奈普利净抑制对恩格列净在慢性射血分数降低心衰患者中疗效与安全性的影响:EMPEROR-Reduced 试验
EMPEROR-Reduced 试验随机纳入 3730 例射血分数≤40% 的心衰患者,其中 727 例(19.5%)基线使用沙库巴曲缬沙坦。预设亚组分析显示,无论是否使用奈普利净抑制剂,恩格列净均降低心血管死亡或心衰住院风险,且联合治疗耐受良好。
要点
- 恩格列净降低心血管死亡或心衰住院风险不受基线沙库巴曲缬沙坦使用影响(交互 P=0.31)。
- 使用奈普利净抑制剂者,恩格列净延缓 eGFR 下降 1.92 mL/min/1.73 m2/年(P=0.016)。
- SGLT2 抑制剂与奈普利净抑制剂联合治疗耐受良好,可预期额外获益。
核心结论
- 在已接受沙库巴曲缬沙坦强化治疗的患者中,恩格列净降低心衰和肾脏事件风险的作用未减弱。
- 联合使用 SGLT2 抑制剂和奈普利净抑制剂可预期产生实质性额外获益。
研究设计与样本
- EMPEROR-Reduced 试验随机、双盲、安慰剂对照研究,纳入 3730 例射血分数≤40% 的慢性心衰患者。
- 患者随机接受安慰剂或恩格列净 10 mg/日,中位随访 16 个月。
- 727 例(19.5%)基线接受沙库巴曲缬沙坦;奈普利净抑制影响为 12 个预设亚组分析之一。
主要发现
- 使用奈普利净抑制剂者收缩压、心率、NT-proBNP 更低,心脏器械使用更多(均 P<0.001)。
- 恩格列净 vs 安慰剂降低心血管死亡或心衰住院风险:使用沙库巴曲缬沙坦者 HR 0.64(95%CI 0.45-0.89,P=0.009)。
- 未使用沙库巴曲缬沙坦者 HR 0.77(95%CI 0.66-0.90,P=0.0008);交互 P=0.31。
- 使用奈普利净抑制剂者恩格列净延缓 eGFR 下降 1.92±0.80 mL/min/1.73 m2/年(P=0.016)。
- 未使用者延缓 1.71±0.35 mL/min/1.73 m2/年(P<0.0001);交互 P=0.81。
临床怎么用
- 对于已使用沙库巴曲缬沙坦的射血分数降低心衰患者,加用恩格列净仍可显著降低心衰事件风险。
- 联合 SGLT2 抑制剂与奈普利净抑制剂耐受良好,可考虑联合用于强化治疗患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We evaluated the influence of sacubitril/valsartan on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patients with heart failure and a reduced ejection fraction. METHODS AND RESULTS: The EMPEROR-Reduced trial randomized 3730 patients with heart failure and an ejection fraction ≤40% to placebo or empagliflozin (10 mg/day), in addition to recommended treatment for heart failure, for a median of 16 months. A total of 727 patients (19.5%) received sacubitril/valsartan at baseline. Analysis of the effect of neprilysin inhibition was 1 of 12 pre-specified subgroups. Patients receiving a neprilysin inhibitor were particularly well-treated, as evidenced by lower systolic pressures, heart rates, N-terminal prohormone B-type natriuretic peptide, and greater use of cardiac devices (all P < 0.001) when compared with those not receiving sacubitril/valsartan. Nevertheless, when compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure in patients receiving or not receiving sacubitril/valsartan [hazard ratio 0.64 (95% CI 0.45-0.89), P = 0.009 and hazard ratio 0.77 (95% CI 0.66-0.90), P = 0.0008, respectively, interaction P = 0.31]. Empagliflozin slowed the rate of decline in estimated glomerular filtration rate by 1.92 ± 0.80 mL/min/1.73 m2/year in patients taking a neprilysin inhibitor (P = 0.016) and by 1.71 ± 0.35 mL/min/1.73 m2/year in patients not taking a neprilysin inhibitor (P < 0.0001), interaction P = 0.81. Combined inhibition of SGLT2 and neprilysin was well-tolerated. CONCLUSION: The effects on empagliflozin to reduce the risk of heart failure and renal events are not diminished in intensively treated patients who are receiving sacubitril/valsartan. Combined treatment with both SGLT2 and neprilysin inhibitors can be expected to yield substantial additional benefits.
引用
- Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021. PMID: 33459776. doi:10.1093/eurheartj/ehaa968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。